Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning

NCT06163781 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2024-02-19
Last updated
2024-05-07

Condition(s) studied

Artificial IntelligenceMachine LearningMicrobiologyEmergency Service, HospitalRandomized Controlled Trial

Investigational drug(s) / intervention(s)

Blood culture prediction tool

Blood culture prediction tool: Machine learning based predicition tool

Study summary

The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are:

* hospital admission rates
* in-hospital mortality
* hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool.

In the comparison group all patients will undergo a blood culture analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age \>= 18 years * Have a clinical indication for a blood culture analysis (according to the treating physician) * Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters) Exclusion Criteria: * Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ * Neutrophil count \< 0.5 \* 109/L * Candidemia or S. aureus bacteraemia in the past 3 months. * Most likely diagnosis of endocarditis/spondylodiscitis/infected prosthetic material * Pregnant or breastfeeding patients * Not capable of giving informed consent

Primary outcome measure(s)

  • 30-day mortality — 30 days

Trial sites (1)

FacilityCityRegionStatus
Amsterdam UMC - location AMC Amsterdam Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06163781 on ClinicalTrials.gov ↗ ← All trials in the Netherlands